Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001

Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)

Published:2018-05-07 Issue:1 Volume:171 Page:151-159
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Daniels Benjamin^ORCID,Kiely Belinda E.,Lord Sarah J.,Houssami Nehmat,Lu Christine Y.,Ward Robyn L.,Pearson Sallie-Anne

Funder

Cancer Australia

National Health and Medical Research Council

Sydney Catalyst

National Breast Cancer Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-018-4804-0/fulltext.html

Reference22 articles.

1. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28(1):92–98. https://doi.org/10.1200/JCO.2008.19.9844

2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. https://doi.org/10.1056/NEJM200103153441101

3. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J, Group CS (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734. https://doi.org/10.1056/NEJMoa1413513

4. Daniels B, Kiely BE, Lord SJ, Houssami N, Lu CY, Ward RL, Pearson S-A (2017) Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001–2016). Breast 38:7–13. https://doi.org/10.1016/j.breast.2017.11.007

5. Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M (2016) Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 159(2):367–374. https://doi.org/10.1007/s10549-016-3933-6

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options;Breast Cancer: Basic and Clinical Research;2024-01

2. Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression;Scientific Reports;2023-05-31

3. The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms;Frontiers in Pharmacology;2023-04-19

4. Long term risk of distant metastasis in women with non‐metastatic breast cancer and survival after metastasis detection: a population‐based linked health records study;Medical Journal of Australia;2022-08-20

5. National Cancer Database trends in surgical resection of the breast primary for stage IV breast cancer;Surgical Oncology;2022-06